Understanding the mechanisms that control UGT2B17 expression in leukemic B cells may provide novel therapeutic approaches in treatment-naïve CLL patients as well as in patients resistant to anti-leukemic treatments. Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.